Company Overview of MORPHOTEK INC.
MORPHOTEK INC. develops a pipeline of preclinical and clinical stage monoclonal antibodies to treat cancer, inflammation, and infectious diseases. Its pipeline of products include Farletuzumab, an investigational monoclonal antibody that targets folate receptor alpha; Amatuximab, an monoclonal antibody that targets mesothelin; MORAb-004, an investigational monoclonal antibody that targets endosialin, MORAb-022, an investigational monoclonal antibody that targets a proinflammatory; and MORAb-066, an investigational monoclonal antibody that targets tissue factor. The company’s products are used to treat ovarian cancer, nonsmall cell lung cancer, melanoma, colorectal carcinoma, sarcoma, mesothe...
210 Welsh Pool Road
Exton, PA 19341
Founded in 1999
Key Executives for MORPHOTEK INC.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Senior Vice President of Research & Development
Chief Finance Officer and Vice President of Project Management
Executive Director of Marketing and Executive Director of Business Development
Vice President of Pilot Plant Operations
Compensation as of Fiscal Year 2014.
MORPHOTEK INC. Key Developments
MORPHOTEK INC. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
MORPHOTEK INC. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Stealth Biologics Announces Research Collaboration with Morphotek
Jul 15 14
Stealth Biologics LLC has announced a research collaboration with Morphotek, Inc. Under terms of the agreement, Stealth Biologics will use its protein design and optimization algorithms to engineer deimmunized biologics for application in cancer therapy. Morphotek will retain the right to develop and commercialize all deimmunized therapeutics resulting from the collaboration.
Morphotek, Inc. Announces Enrollment in Phase I Solid Tumor Study
Oct 16 13
Morphotek, Inc. has opened enrollment in a Phase I clinical study with MORAb-004 in pediatric patients with relapsed/refractory solid tumors. The open-label Phase I study will assess the safety, tolerability and pharmacokinetics of MORAb-004 administered in weekly intravenous infusions in pediatric patients. MORAb-004 is an investigational monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1). The target is found to be expressed on the cell surface of cells called pericytes that are part of the tumor blood vessel architecture, as well as on fibroblast cells that are part of the tumor stroma. Morphotek obtained exclusive worldwide rights to develop and commercialize this antibody from the Ludwig Institute for Cancer Research (LICR).
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|